Lv Qiulan, Li Zhiyuan, Sui Aihua, Yang Xiaomin, Han Yafei, Yao Ruyong
Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Front Microbiol. 2022 Aug 18;13:977187. doi: 10.3389/fmicb.2022.977187. eCollection 2022.
Type 2 diabetes mellitus (T2DM) and T2DM-related complications [such as retinopathy, nephropathy, and cardiovascular diseases (CVDs)] are the most prevalent metabolic diseases. Intriguingly, overwhelming findings have shown a strong association of the gut microbiome with the etiology of these diseases, including the role of aberrant gut bacterial metabolites, increased intestinal permeability, and pathogenic immune function affecting host metabolism. Thus, deciphering the specific microbiota, metabolites, and the related mechanisms to T2DM-related complications by combined analyses of metagenomics and metabolomics data can lead to an innovative strategy for the treatment of these diseases. Accordingly, this review highlights the advanced knowledge about the characteristics of the gut microbiota in T2DM-related complications and how it can be associated with the pathogenesis of these diseases. Also, recent studies providing a new perspective on microbiota-targeted therapies are included.
2型糖尿病(T2DM)及T2DM相关并发症[如视网膜病变、肾病和心血管疾病(CVDs)]是最常见的代谢性疾病。有趣的是,大量研究结果表明肠道微生物群与这些疾病的病因密切相关,包括异常肠道细菌代谢产物的作用、肠道通透性增加以及影响宿主代谢的致病性免疫功能。因此,通过宏基因组学和代谢组学数据的联合分析来破译与T2DM相关并发症的特定微生物群、代谢产物及相关机制,可为这些疾病的治疗带来创新策略。据此,本综述重点介绍了有关T2DM相关并发症中肠道微生物群特征及其与这些疾病发病机制关联的前沿知识。此外,还纳入了近期为微生物群靶向治疗提供新视角的研究。